Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 ...

Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced the interim clinical results from its ongoing Phase 1/2 first-in-human trial ...

UC Santa Barbara researchers and collaborators from campus biotech spinoff Integrated Biosciences, as well as Harvard, MIT, Princeton and genomics company Illumina Ventures are using optogenetics — ...

A KAIST research team led by Professor Won Do Heo (Department of Biological Sciences) has developed an optogenetic platform, RELISR (REversible LIght-induced Store and Release), that enables precise ...

Ray Therapeutics has secured the European Medicines Agency’s PRIME designation for RTx-015, an optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The recognition is ...

Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective, SriniVas R. Sadda, MD, discusses his paper on Nanoscope’s MCO-010 optogenetic ...

A landmark study published in Cell has unveiled a first-of-a-kind optogenetic screening platform, developed by scientists at Integrated Biosciences, a biotechnology company integrating optogenetics, ...

A team led by Professor Ed X. Wu and Dr. Alex T. L. Leong has achieved a major breakthrough in understanding how the brain ...